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Abstract
Background: As the high throughput sequencing efforts generate more biological information, scientists from
different disciplines are interpreting the polymorphisms that make us unique. In addition, there is an increasing
trend in general public to research their own genealogy, find distant relatives and to know more about their
biological background. Commercial vendors are providing analyses of mitochondrial and Y-chromosomal markers
for such purposes. Clearly, an easy-to-use free interface to the existing data on the identified variants would be in
the interest of general public and professionals less familiar with the field. Here we introduce a novel metadatabase
YDHS that aims to provide such an interface for Y-chromosomal DNA (Y-DNA) haplogroups and sequence variants.
Methods: The database uses ISOGG Y-DNA tree as the source of mutations and haplogroups and by using genomic
positions of the mutations the database links them to genes and other biological entities. YDHS contains analysis
tools for deeper Y-SNP analysis.
Results: YDHS addresses the shortage of Y-DNA related databases. We have tested our database using a set of
different cases from literature ranging from infertility to autism. The database is at http://www.semanticgen.net/ydhs
Conclusions: Y-chromosomal DNA (Y-DNA) haplogroups and sequence variants have not been in the scientific
limelight, excluding certain specialized fields like forensics, mainly because there is not much freely available
information or it is scattered in different sources. However, as we have demonstrated Y-SNPs do play a role in various
cases on the haplogroup level and it is possible to create a free Y-DNA dedicated bioinformatics resource.
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Background
The human Y chromosome has unique characteristics
which make it the subject of intense research. Indeed, it has
been 10 years now since the Y chromosome was initially
sequenced in 2003. Unlike the 22 autosomal pairs of
human chromosomes, the Y chromosome does not exist
as a homologous pair. Therefore, the majority of the
Y chromosome does not undergo recombination and
is transmitted to male offspring in a virtually unchanged
form, resulting in vertical transmission of haplotypes.
Some genetic polymorphisms of the Y chromosome are
associated with observed Y-linked phenotypic differences.
The uniparental inheritance of mutations results in differ-
ent “at risk” haplotypes among different paternal lineages
[1], which are frequently dependent on ethnicity and the
extent of admixture among populations. The field of
medical genetics has utilized this pattern of heritability to
study the relationship of specific mutations in Y chromo-
some genes and haplotypes which influence susceptibility
to a number of of physical and mental disorders. The
human Y chromosome consists of 86 genes coding 23
proteins (506 genes if pseudogenes are included) according
to Ensembl e72 build. The genes in the Y chromosome
are organized to specific chromosomal regions as illustrated
in Fig. 1.
Methods
We have developed a novel database YDHS (http://semantic
gen.net/ydhs) to integrate haplogroup, genetic and genomic
information regarding human chromosome Y. The
database contains mutation and haplogroup data from
the International Society of Genetic Genealogy (ISOGG;
http://www.isogg.org/) consortium compiled in June 2013
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(Fig. 1). The specific coverage of mutations per genes in
haplogroups and the general distribution of mutations per
haplogroup are illustrated in Fig. 2 and Fig. 3, respectively.
We have developed an automated parser that transforms
the Y-DNA haplotree and corresponding mutations
with their positions in Grc37 build version to a MySQL
database format for easy querying. Citations of the articles
where SNPs were first introduced are also included in the
database, and the citations are searchable via the web user
interface, and a direct link is included if provided by
ISOGG. Genomic information from Ensembl (GRch37)
was integrated to our database using SNP positions to find
Fig. 1 The image contains multiple tracks from YDHS database: starting from the outer rim with Gene Ontology (GO), Gene, SNP and finally the
innermost track is OrphaNet. In the Gene Ontology track biological process is viewed in red, molecular function in black, and cellular component
in green. The height of the GO bar corresponds to the amount of ontologies linked to the gene. In the Gene track the positive strand is colored
black and the negative one in red. The third track counting from the outer rim is the SNP track where different types of SNPs have different color
schema. From up to down: T- > G is in light blue, T- > C is in blue, T- > A is in dark blue; G- > T is in light grey, G- > is in grey, G- > A is in black;
C- > T is in light green, C- > G is in green, C- > A is in dark green; A- > G is in pink, A- > C is in red, A- > T is in dark red. In the innermost track,
OrphaNet and OMIM, the higher the bar is the more diseases has been reported for that gene or region. The grey plot on top of the SNP track
indicates the frequency of SNPs in that region. There are some clearly visible 'hotspots' where a lot of mutations have clustered
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out which SNPs are located inside genes and which
involve amino acid sequences of the proteins. The
genomic location can be visualized by clicking the
mutation position, which opens up the location in the
UCSC Genome Browser (http://genome.ucsc.edu/), or
if there is a reference SNP available one can use the
provided link to dbSNP (http://www.ncbi.nlm.nih.gov/
SNP/). Gene Ontology (http://www.geneontology.org/),
InterPro (http://www.ebi.ac.uk/interpro/) and UniProt
(http://www.uniprot.org) data were added to the database
using gene identifiers as unique keys, allowing the user to
browse the functional information of genes and proteins by
family based classification, domain and function prediction
alongside the manually annotated entries to see what the
gene/protein does in the human body. Relevant data about
the potential diseases associated with the gene of interest
were also added to the database. Hyperlinks to entries in
the OMIM database (http://www.ncbi.nlm.nih.gov/omim)
and OrphaNet (http://www.orpha.net) were associated with
the respective genes. Egenetics (http://www.sanbi.ac.za/
resources/software-downloads/evoc/) was used as the
source of expression data separated by cell type, anatom-
ical system and pathology. If the protein had a structure
stored in Protein Data Bank PDB (http://www.rcsb.org) it
was also hyperlinked in YDHS under the “Extra” tab.
The majority of the polymorphisms are located outside
of coding regions of genes, and not all coding-region









































































































































































































































































































































































































































































Fig. 3 The overall distribution of mutations per haplogroup. Data derived from ISOGG on July 2013
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of polymorphisms were assessed by using Variant
Effect Predictor (VEP). Every polymorphism derived
from the ISOGG database was subjected to VEP by
Representitational State Transfer (REST) interface
(http://rest.ensembl.org/) provided by EBI, the European
Bioinformatics Institute. VEP consists of two predictor
programs, SIFT (http://sift.jcvi.org/) and PolyPhen
(http://genetics.bwh.harvard.edu/pph2/). VEP is good for
predicting mutations affecting protein function, but
additional tools to increase the prediction accuracy
for rare polymorphisms were considered important.
PROVEAN (http://provean.jcvi.org/) and Variation
Reporter (http://www.ncbi.nlm.nih.gov/variation/tools/
reporter) from NCBIs ClinVar toolkit were added to
increase the prediction capabilities of YDHS. These
tools used in sync can provide valuable information
when the deleterious potential of a mutation is otherwise
difficult to assess.
We also provide information whether the gene of
interest is under positive selection using the Selectome
database (http://selectome.unil.ch/). In addition, we provide
information regarding repeats for the gene of interest
via UCSC genome tracks. The location and popula-
tion of the highest frequency of the haplogroup of
interest is browseable by clicking the haplogroup
(where) link provided that the information is available.
The haplogroup location and population lists were
compiled from Wikipedia (https://en.wikipedia.org/wiki/
Human_Y-chromosome_DNA_haplogroup) on June 2013.
The proteomics part of YDHS consist of protein-
protein interaction information via PSICQUIC (Proteomics
Standard Initiative Common QUery InterfaCe) service as
proposed by the HUPO Proteomics Standard Initiative. We
have used EBIs PSICQUIC View to give us access to 28
different proteomics databases (http://www.ebi.ac.uk/Tools/
webservices/psicquic/view/main.xhtml). The user can also
visualize the protein-protein interaction graphs from
STRING database in YDHS with one click from the menu.
If the user would like to view the orthologs of the gene of
interest, it can be done via the Gene IDs tab in the
database. Ortholog entries come from InParanoid7
database (http://inparanoid.sbc.su.se).
The YDHS database is built on top of MySQL database
and outputs the information as JavaScript Object Notation
(JSON) which is parsed via HTML5 if the user’s browser
is capable of handling it; otherwise standard AJAX calls
are used. Ease of use was considered to be of importance
and thus the user interface is simple and stripped from
extraneous functionality commonly found on various core
databases for biological information. YDHS provides a
data export option in JSON format for computational
parsing and for input to external analysis programs.
The integration of different databases is done by dedi-
cated PHP and Perl scripts. YDHS was used for the
exploratory analysis of haplogroups and traits covered in
this article. The Fig. 1 was drawn using Circos software
(http://circos.ca/) and YDHS data.
Results and discussion
Since there are altogether 3896 SNPs in the ISOGG
Y-DNA tree (December 2013) and many more unsubstan-
tiated ones, we decided to show the use of YDHS database
using case examples. We chose four traits that have a
linkage to Y chromosome according to the literature.
Using these cases we tested how well YDHS can concur
with already published results and whether the use of our
integrative approach could yield additional information
about the traits.
Case: infertility
One of the most frequent subjects of Y chromosome-re-
lated medical genetics is male infertility. Microdeletions in
the q arm are one of the most common causes of infertil-
ity, especially those which result in the loss of some or all
of the azoospermia factor (AZF) gene [2, 3]. These
mutations can result in oligospermia or azoospermia,
cryptorchidism [4], and aneuploidy [5]. Although mutations
on the Y chromosome should be preserved in male
offspring that these men do produce, it is unclear whether
specific haplotypes are associated with such microdeletions.
Idiopathic reduced sperm counts are associated with
microdeletions in Danish men with haplotype hg26
[6]. Hg26 is a rare haplotype among European males
[7] and it may continue to decline if it remains associated
with subfertility. 3 of 4 Japanese fertility patients with
AZFa microdeletion were from the same haplogroup, D2b
[8]. D2b is also associated with AZFc microdeletions [9].
However, this haplogroup is common in Japan [10] and
the prevalence of microdeletions might be proportionate
with prevalence of that haplotype.
The haplogroup D2b was refactored from ISOGG
nomenclature in 2011, but the data is available as
haplogroup D2a. Our YDHS database contains only one
mutation for haplogroup D2a; namely M116.1. However,
interestingly M116.1 is located inside TXLNG2P pseudo-
gene. A recent study by Sato et al. [11] specified the
haplogroup involded in azoospermia in Japanese men to
be D2*. For that haplogroup there are 11 mutations in the
database of which 8 are located inside gene regions and
one in the TXLNG2P pseudogene. Chromosome Y hosts
23 AZF genes (Table 1). The AZF gene KDM5D has the
greatest coverage of ISOGG mutations, namely 861,
followed by DDX3Y with 320 mutations. In many cases,
there exists no relationship between microdeletions,
infertility, and haplotype [6, 12]. However, the use of
YDHS facilitates linking mutations and genes in a
haplogroup thus making it possible to compare sub-
haplogroups inside complex diseases like infertility.
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Other mechanisms of Y chromosome-associated male
infertility have also been identified or hypothesized for
subfertile but karyotypically normal males. Genomic
instability is one such mechanism, in which either
chromosomal or microsatellite instability can result in
spermatic aneuploidy [13, 14]. A non-exclusive possibility
is that dysfunctional androgen receptors may result in
infertility in men with normal androgen levels [15].
These and other abnormalities which inhibit fertility could
be inherited via nontraditional mechanisms (e.g. genetic
mosaicism, genomic imprinting), which might result in
deviations from the classic, vertical transmission of Y
chromosome haplotype from father to son [16].
Case: reproductive cancers
The anomalies which result in reproductive dysfunction
often predispose men to the development of other
urologic ailments, including prostate cancer [17]. Indeed,
just as genomic instability and Y chromosome deletions
contribute to infertility, both can also contribute to
carcinogenesis [13, 18]. Y chromosome deletions are
one of the most common genetic anomalies among
prostate cancer patients [19] and include the loss of
various genes, including TSPY, PRY, EIF1AY, TMSB4Y,
ZFY, BPY1, KDM5D, RBMY1A1, BPY2, and SRY [20–22].
Furthermore, there is a positive association between the
number of gene losses and the stage/grade of prostate
cancer [22].
TSPY is perhaps the most prominent Y-chromosome
gene whose loss contributes to prostate cancer. Low
copy numbers are associated with higher risk of prostate
cancer [23, 24]. However, upregulation of products in
the protocadherin gene family are involved in aggressive,
apoptosis-resistant prostate cancers, as evidenced by
cell lines which, after selection for apopotosis resistance,
produce protocadherin-PC [25]. Furthermore, the proto-
cadherin gene PCDH11Y, appears to be associated with
aggressive prostate cancers [26, 27] but the haplogroup
Table 1 Shows the names of genes located in chromosome Y with the amount of respective mutations alongside with the
frequency of GO terms






Gene length (bp) MIM Gene
Accession(s)
Orphanet Ids
ENSG00000012817 KDM5D 861 No 55 41,074 426,000 1646
ENSG00000067048 DDX3Y 320 No 21 16,371 400,010 -
ENSG00000114374 USP9Y 250 No 12 159,604 400,005 1646
ENSG00000129873 CDY2B - No 8 2810 400,018 -
ENSG00000131002 Cyorf15A / Cyorf15B - No 0 38,961 400,031 -
ENSG00000157828 RPS4Y2 12 No 6 24,868 400,030 -
ENSG00000169789 PRY - No 0 24,240 400,019,400,041 -
ENSG00000169807 PRY2 - No 0 24,251 400,019,400,041 -
ENSG00000169953 HSFY2 - No 18 42,295 400,029 -
ENSG00000172288 CDY1 - No 10 2785 400,016 -
ENSG00000172468 HSFY1 - No 24 42,292 400,029 -
ENSG00000182415 CDY2A - No 8 2810 400,016,400,018 -
ENSG00000183753 BPY2 - No 10 31,646 400,013 -
ENSG00000183795 BPY2B - No 5 31,647 400,013 -
ENSG00000185894 BPY2C - No 5 31,647 400,013 -
ENSG00000187191 DAZ3 - No 16 50,410 400,027 1646
ENSG00000188120 DAZ1 - No 23 69,739 400,003 1646
ENSG00000198692 EIF1AY 108 No 7 17,429 400,014 -
ENSG00000205916 DAZ4 - No 27 73,175 400,003,400,026 1646
ENSG00000205944 DAZ2 - No 48 71,909 400,026 1646
ENSG00000234414 RBMY1A1 1 No 19 37,954 400,006 1646
ENSG00000244646 XKRY2 - No 0 8417 - -
ENSG00000250868 XKRY - No 0 8418 - -
If the gene has a very high number of GO terms associated, it can be argued that the gene is functionally active and probably part of a signaling network. It can
be stated that genes having a lot of mutations also have a very high number of ontologies, except for EIF1AY. Table 1 reveals also the length of the gene so that
the density of mutations per gene can be addressed. The MIM and OrphaNet codes are also included to show how the genes are linked to various
medical conditions
Tiirikka and Moilanen Clinical and Translational Medicine  (2015) 4:20 Page 5 of 9
link is still under research. There is apparently little
research regarding the effect of Y-haplotype on these
prostate cancer-contributing factors (but see [28]).
However, using Y-linked short tandem repeats (STRs), a
study of Malaysian men suggests that prostate cancer
development is more common among the haplotype
CAAA [29]. Furthermore, a study among men of European
descent suggests that the haplogroup E1b1b1c, which is
more common among Ashkenazi Jews than other
Europeans, might be associated with the development
of prostate cancer [30]. Interestingly, PCDH11Y is the
only gene under positive selection out of the 506 Ensembl
genes in YDHS and it might have a deeper role on Y
haplogroup and prostate cancer related questions.
In YDHS there was only one SNP linked to haplogroup
E1b1b1c, namely V6. The gene involved in this mutation
is ENSG00000092377, also known as TBL1Y by the
HUGO gene nomenclature committee, translating into 4
proteins (3 splice variants). The OMIM entry linked to
this gene is 400,033. TBL1Y is an X-degenerate gene that
is a homolog of TBL1X [23]. The anatomical system
for this gene is germinal center and the cell type is
B-lymphocyte according to YDHS. There are altogether
19 variations for this gene out of which 3 are deleterious,
7 are benign and the rest do not have any prediction
regarding the outcome. Interestingly NCBIs Variation Re-
porter shows only 3 variations. The gene TBL1Y is not
under positive selection.
Gonadoblastoma, a germ cell tumor, is also Y-linked.
Gonadoblastomas have a high frequency in XY females
[31–33], suggesting a link between Y chromosome
dysfunction and tumor development although it could
be related to erroneous gender differentiation during
the fetal period. Unlike prostate cancer, in which low
TSPY expression is associated with high risk, high TSPY
expression is a putative cause of gonadoblastoma [34, 35].
TSPY is also expressed in seminomas, a testicular germ
cell tumor [34].
Case: heart disease
Heart disease has a higher prevalence among males than
females [36]. Although both male and female heart
disease patients have altered gene expression from
healthy patients, Y chromosome transcripts are dra-
matically upregulated among male Idiopathic Dilated
Cardiomyopathy (IDCM) patients [37]. Of these genes,
USP9Y is overexpressed in heart disease patients; among
black populations in the UK, the most common USP9Y
haplotype (TBL1YA USP9YA; 79.1 % prevalence) is pro-
tective against heart disease [38]. Although this genotype
was not associated with reduced likelihood of heart
disease where it occurred among white British men, this
apparent lack of protection may be due to low statistical
power owing to its infrequent occurrence among whites
(4.9 % prevalence). Other haplotypes also affect heart
disease susceptibility among British men of European
origin; haplogroup I is associated with a 50 % higher
risk of developing coronary artery disease than other
lineages [39]. Haplogroup I is a common haplogroup in
the UK, second only to R1b1b2 (prevalence 14.5-17.0 %,
70.0-72.7 %, respectively; [39]).
Interestingly, the predisposition of haplogroup I to
coronary artery disease seems attributable to high levels of
inflammatory immune responses rather than traditional
coronary risk factors (e.g. lipid profiles; [39]). However, in
a separate study, no significant association between haplo-
type and cardiovascular risk factor-associated SNPs were
found among British men of European origin [40]. The
haplogroup I contains 53 mutations in YDHS database
and 14 of those are located inside genes giving rise to 69
proteins. The location of haplogroup I genes seems to be
in the long arm q11.2 and its sub-cytobands. The
common OrphaNet denominator for a vast majority of
haplogroup I genes appears to be “partial chromosome Y
deletion” (ID:1646). The haplogroup R1b1b2 was refac-
tored to R1b1a2 by the ISOGG consortium in 2011. There
are 10 mutations stored in YDHS database for R1b1a2
haplogroup and interestingly only one mutation hits a
gene region, namely eukaryotic translation initiation factor
1A (EIF1AY). The small amount of repeats is surprising,
only two (L1M4 and AluY) in the gene; one would expect
a lot more based on the repeat rich nature of the chromo-
some Y. EIF1AY is not under positive selection and it
codes for two proteins that have 3 unique variations
altogether. The variation effect predicting algorithms were
unable to determine whether these mutations were
deleterious or not. SIFT predicted one tolerated and
one deleterious mutation, whereas PolyPhen flagged
two mutations unknown. Both of the programs failed
to produce a prediction for the known reference SNP,
rs58802313.
Case: autism
Autism spectrum disorders are far more prevalent
among males than females, ranging from 4:1 universally
to 23:1 among the neurologically normal [41]. Thus, a role
of Y-linked genes has long been suspected for autism and
related disorders (reviewed by [42]). Indeed, there is a high
prevalence of unusual SNPs on the Y-chromosome genes
TBL1Y (transducin (beta)-like 1) and NLGN4Y (neuroligin
4, Y-linked) in autistic males [43]. Y-chromosome
aneuploidy is associated with a higher than average
rate of autistic disorders [44], with 28.3 % of XXYY males
exhibiting autism [45]. There are 568 mutations in TBL1Y
stored in YDHS database but it seems that haplogroup T
has the most mutations (44) for TBL1Y gene. Haplogroup
T is common in some parts of Asia, Southern Europe and
in Africa. Interestingly haplogroup A, which is prevalent
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also in Africa had a very high amount of mutations (43)
too, although it has a high number of mutations in gene
regions (Fig. 2).
Results from studies examining the heritability of autism
and its linkage to specific haplotypes are mixed, however.
Among European-American males, 4 of 9 unnamed
haplotypes were significantly over- or under-represented
in normal vs. autistic groups [43], suggesting that certain
haplotypes are protective or contributive, respectively.
Anyhow, there was no reported relationship of haplotype
with autism among French, Swedish, and Norse men [46].
The haplogroup I is the most common one for Nordic
countries and northernmost Europe [47].
Y-SNP distribution and diseases using YDHS database
Visual inspection shows three distinct clusters of Y-SNP
rich regions in Fig. 1 and since the location is shown
in intervals of 1 Mb it is easy to identify the highly
polymorphic regions. In this section we focus on area
between roughly 22 and 24 Mb as visualized in Fig. 4
to illustrate the amount of information in YDHS. As
explained in the Fig. 1 legend, the outer rim is reserved
for the functional annotation part of the genes influenced
by Y-SNP illustrated by bar diagram. Functional annota-
tion is conducted using Gene Ontologies and the results
are further split in to three color categories: biological
process is viewed in red, molecular function in black and
cellular component in green. The height of the bar and
the abundance of these colors tells the user how much
information the gene has e.g. higher bar means more on-
tologies are linked to it telling the annotation is more
thorough. The color of the bar expresses the depth of the
annotation process i.e. entirely green bar reveals the
user that the vast majority of annotations are location
thus cellular component related. This is categorization
is advantageous since it offers an instant way to simplify
complex datasets.
The layer below the annotation part illustrates the
genes and the frequency of Y-SNPs as an area digram.
The genes are color coded depending on the strand;
genes located on positive strand are black and the ones
on negative strand are red. The more there are Y-SNPs
clustered, the higher the gray area of the plot, visualizing
the highly polymorphic areas. The layer below the gene
track is devoted to the Y-SNPs involved having the color
schema explained in Fig. 1 legend.
The innermost layer is reserved for evidence of
diseases linked to OrphaNet and/or OMIM. The higher
the red bars are the more diseases are connected with
the illustrated region. In Fig. 4 we have an interesting
cluster of Y-SNPs in region 21,8-21,9 Mb. The genetic
disorder linked to this region is OMIM #426000 and it
could play a part in Y-linked spermatogenic failure as
already explained in the AZF gene section. The gene
involved is KDM5D. The KDM5D protein is, however, quite
abundant according to PaxDB database (http://pax-db.org/
#!protein/Q9BY66) which could also explain the high
number of clustered mutations but it does not explain
Fig. 4 A more thorough look into Y-chromosome variant composition for the region between 22 Mb and 24 Mb
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the Y chromosome link as the YDHS database does.
Additional information can be found from Table 1 as
the number of Gene Ontologies (55).
Currently there are 861 mutations stored in YDHS for
KDM5D gene, and in terms of haplogroups the muta-
tions are quite evenly distributed among haplogroups;
mutation numbers per haplogroup vary between 7 to 49.
The most common haplogroups were R1a and R1b with
49 and 35 mutations, respectively. The haplogroups are
common in Europe, South and Central Asia and parts of
Africa. R1a and R1b are not among the most mutation-
rich haplogroups as can be seen in Fig. 3. Interestingly
subclades deriving from R1a are very well represented in
the Y-SNP pool e.g. R1a1a1b1a3b. The same order applies
to Fig. 2, which provides Y-SNP distribution to gene areas
solely, since our example is a functional gene.
Conclusions
During its journey chromosome Y has had its ups and
downs – from being called a boring “dud” [48] or genomic
wasteland to the recent years’ rollercoaster ride of whether
it is going to vanish from the face of the earth or restruc-
ture itself [49]. However despite the interest and efforts
there has been very little research in embedding haplogroup
information and variations to the genomic data regarding
various diseases and conditions. At the time of writing this
article there was no service or database for integrating Y
chromosome haplogroups and genomic data from public
resources. Integrating this data without a dedicated
database would have required substantial manual work
and bioinformatics expertise.
Now in YDHS, we have combined multiple tools under
one resource that enables the user to e.g. browse through
haplogroups and focus on certain SNPs distinct to that
haplogroup and reveal where they are located and whether
they have a link to a disease or condition and view the
related genes and interactions. In addition, the user
can run a set of predictor programs to see if the SNP
is pathogenic or not and narrow down the geographic
location of the haplogroup. We also provide text
search to find articles where the SNP of interest was
first introduced. The YDHS database provides an easy
and convenient one-stop-shop to do translational research
with chromosome Y without the need to browse around
multiple databases or tackle with different data formats.
As shown with the cases described here, haplogroups
may provide an interesting insight to a number of genetic
conditions.
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